Apollomics Inc.
Apollomics Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies. Its lead asset is vebreltinib (APL-101), a c-Met inhibitor being developed for non-small cell lung cancer and other advanced tumors with c-Met alterations, with development activity in the United States and international markets outside Mainland China and Macau.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueDevelopment of vebreltinib (APL-101), a selective c-Met inhibitor for cancer.
Out-licensing and regional development rights for vebreltinib in selected territories.
Pre-commercial research, clinical trials, and regulatory development activities.
Customers
Apollomics does not sell broadly to end consumers; its economic counterparties are licensing partners, clinical investigators, hospitals, and trial sites supporting drug development. In commercial terms, value is created through regional partnering arrangements for vebreltinib and future oncology collaborations rather than mass-market product sales.
Pharmaceutical partners that acquire regional rights to develop and commercialize vebreltinib.
Hospitals and research centers that administer studies and enroll patients.
Patients with non-small cell lung cancer or other c-Met altered tumors enrolled in trials.
Potential partners that may support later-stage development and market access.
Strategy
Apollomics’ strategy centers on advancing vebreltinib through clinical development while retaining broad control over ex-China rights. The company also seeks to use regional partnerships to extend reach, fund development, and preserve flexibility for future commercialization opportunities.
Clinical data and regulatory progress determine the asset's long-term value.
Licensing can provide non-dilutive capital and local market expertise.
Maintaining ownership across key markets increases flexibility for future deals.
Geography
Apollomics is headquartered in the United States and develops vebreltinib across the U.S., Europe, and the broader Asia-Pacific region. The company has retained rights outside Mainland China and Macau, so its commercial footprint is shaped by regional licensing, clinical trial execution, and partner-dependent expansion across multiple jurisdictions.
Risks
Apollomics faces the classic risks of a clinical-stage biotech company: trial failure, regulatory delay, and dependence on external capital and partners. The company also has geographic and contractual exposure because its lead asset is monetized through regional rights and collaborations, making execution and partner quality important to future value creation.
- Clinical development failureImpact: CriticalLikelihood: Medium
Vebreltinib is still in clinical development and may not achieve efficacy or safety targets.
Exposure: Lead asset vebreltinib
- Financing dependenceImpact: HighLikelihood: High
Clinical-stage biopharma companies typically require repeated external funding to support trials and operations.
Exposure: Working capital and development funding
- Partner execution riskImpact: HighLikelihood: Medium
Regional licensing and commercialization outcomes depend on counterparties' diligence and investment.
Exposure: Asia and future ex-China partnerships
- Regulatory and trial timing riskImpact: MediumLikelihood: High
Drug development timelines are vulnerable to FDA and ex-U.S. review processes.
Exposure
Accounting
Judgemental itemsUpfront payments from regional agreements affect when revenue is recorded and can create lumpy periods.
Impact: 2025 revenue was tied to an Asia licensing upfront payment
Development assets require periodic recoverability testing and may be written down if prospects weaken.
Impact: Impairment charges affected reported loss
Valuation of financial assets, liabilities, and convertible instruments can affect profit or loss.
Impact: Non-cash gains and losses may distort comparability
Bridge financing with conversion features requires assessment of liability and equity treatment.
Impact: Can influence balance sheet classification and dilution
Similar listed companies
Publicly listed companies with a comparable business focus.
Avalo Therapeutics, Inc.
AVTX · Pharmaceutical Preparations
Exelixis, Inc
EXEL · Biological Products, (No Diagnostic Substances)
Exelixis is a U.S.-based oncology company built around cabozantinib, which it markets as CABOMETYX and COMETRIQ and uses as the core of its commercial revenue base.
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
SELLAS Life Sciences Group, Inc.
SLS · Pharmaceutical Preparations
SELLAS Life Sciences Group is a U.S.-based late-stage clinical biopharmaceutical company focused on developing cancer therapeutics.
Alumis Inc
ALMS · Pharmaceutical Preparations
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Last updated: 28/09/2026